The Medicines Company (MDCO) is licensing the rights to cholesterol-lowering drug ALN-PCS from...

|About: The Medicines Company (MDCO)|By:, SA News Editor

The Medicines Company (MDCO) is licensing the rights to cholesterol-lowering drug ALN-PCS from Alnylam Pharmaceuticals (ALNY), with Medicines paying $25M up front, as much as $180M in milestones, and then royalties. The treatment inhibits a protein called PCSK9 and is seen as an alternative to statins such as Lipitor. However, ALN-PCS is only in Phase I trials.